Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site


Julien Masliah-Planchon


Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239


J. Masliah-Planchon1, M. Kamal2, E. Borcoman2, E. Girard3, P. Gestraud3, G. Bataillon4, A. Vincent-Salomon4, C. Lecerf2, C. Callens5, S. Antonio1, C. Franck1, O. Mariani4, I. Bieche5, C. Le Tourneau2, V. Servois6

Author affiliations

  • 1 Department Of Genetics, Institut Curie, 75005 - Paris/FR
  • 2 Department Of Drug Development And Innovation, Institut Curie, 75005 - Paris/FR
  • 3 Inserm U900 Research Unit, Institut Curie, 92210 - Saint-Cloud/FR
  • 4 Department Of Pathology, Institut Curie, 75005 - Paris/FR
  • 5 Department Of Genetics, Institut Curie, Paris/FR
  • 6 Department Of Radiology, Institut Curie, 75005 - Paris/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4084


High throughput molecular screening of solid tumours using core needle biopsies (CNB) allows the identification of actionable molecular alterations. Several reports revealed that success rate of genomic analyses based on CNB is around 70% with failures being mostly related to low proportion of tumour cells. Although several studies have demonstrated the utility of small biopsy specimens for molecular testing, there remains debate as to the sensitivity of CNB to detect actionable alterations compared to the less invasive fine needle aspiration (FNA). We aim to prospectively evaluate the ability of FNA to detect molecular alterations identified on CNB in cancer patients (pts) included in SHIVA02 trial.


In-house targeted sequencing amplicon based panel (Illumina TSCA 99.3 Kb, 1,504 amplicons covering 87 genes) was used to identify pathogenic variants and gene copy number alterations (CNVs) in both CNB and FNA for pts enrolled in the SHIVA02 trial (NCT03084757).


CNB and FNA specimen from 39 pts enrolled in the SHIVA02 trial were assessed. Main tumour locations were breast (17pts, 44%), pancreatic (4pts, 10%), and colorectal cancers (3pts, 8%). 91 somatic variants were identified in both specimens with a good correlation of variants’ allelic ratios (r: 0.772). CNV profiles of CNB and FNA were concordant. When taking into account molecular alterations validated during the molecular biology board, 88 alterations (55 variants and 35 CNVs) were reported among which 69 alterations (78%) where concordant between CNB and FNA. Among the 50 actionable alterations, only 12 (3 variants and 9 CNVs) (24%) were discordant between FNA and CNB. Main discordances were related to homozygous deletions and amplifications but false negative results were not related to FNA samples alone (5 CNVs in favour of FNA versus 4 in favour of CNB).


Comparative analyses of molecular alterations in CNB compared to FNA showed high concordance in terms of variants as well as CNVs identified. FNA could therefore be easily used in routine diagnostics workflow and clinical trials for tumour molecular screening with the advantage of being minimally invasive.

Clinical trial identification

NCT03084757 SHIVA02; Trial release date: April 1, 2017.

Editorial acknowledgement

Legal entity responsible for the study

Institut Curie.


MSD Avenir Fundation.


C. Le Tourneau: Advisory / Consultancy: MSD, BMS, Merck Serono, AstraZeneca, Novartis, Roche, Nanobiotix. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.